TrialThe Lancet. Respiratory medicine2019

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Martin Reck et al.PubMed ↗Publisher ↗

No numbers read from the abstract.